Abazistobart is an immunostimulant and antitumor agent targeting programmed cell death protein 1 (PDCD1). This chimeric humanized monoclonal antibody specifically binds to PDCD1, blocking associated signaling pathways, thereby activating the immune system to exert antitumor effects. Abazistobart holds promise for cancer research applications.